ISEC Healthcare Ltd · SGX:40T
ISEC Healthcare — H1 2017 Earnings Presentation
21 slides from ISEC Healthcare's earnings presentation, Aug 8, 2017
Slide 1: Corporate Presentation – 6 months ended 30 June 2017
Corporate Presentation 6 months ended 30 June 2017 Page 0
Slide 2: Sponsor disclaimer
This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist
Slide 3: Table of Content
Table of Content Business Overview Industry Overview Business Strategy and Expansion Plans Use of Proceeds 6 months ended 30 June 2017 Financial Highlights Page 2
Slide 4: Business Overview
Business Overview Page 3
Slide 5: Business Overview
Business Overview • Specialised Health Services – Medical eye care service provider • ISEC is a comprehensive medical eye care service provider, with ambulatory surgical centres in Malaysia (Kuala Lumpur, Penang, Malacca & Sibu) and provides specialist medical ophthalmology services to Lee Hung Ming
Slide 6: Competitive Strengths of the Group
Business Overview Competitive Strengths of the Group 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well pos
Slide 7: Industry Overview
Industry Overview Page 6
Slide 8: Key Drivers for Private Ophthalmology
Industry Overview Key Drivers for Private Ophthalmology AGEING POPULATION with large elderly 25.9% of population in Malaysia above 40 years old in 2013, expected to patient group suffering from cataract, grow at CAGR of 1.7% from 2013 to 2018 glaucoma, AMD, dry eyes or vitreoretinal diseases as th
Slide 9: Key Drivers for Private Ophthalmology (cont'd)
Industry Overview Key Drivers for Private Ophthalmology (cont’d) Medical tourism based healthcare expenditure forecast to grow at 26.7% GOVERNMENT SUPPORT IN PROMOTING CAGR from 2009 to 2018 in Malaysia MEDICAL TOURISM leading to generation of additional demand for medical services Medical touri
Slide 10: Business Strategy and Expansion Plans
Business Strategy And Expansion Plans Page 9
Slide 11: Our Business Strategies
Our Business Strategies To reach more patients in locations where we currently Growing the ISEC operate, as well as new locations such as major cities or Brand and locations in Peninsular Malaysia, East Malaysia and Singapore Expanding into To expand via setting up of subsidiaries, JV, expand ex
Slide 12: Expansion Plans – Business expansion in the Asia Pacific
Expansion Plans Business expansion in the Asia pacific region (including Malaysia Malaysia & and Singapore) Singapore Target Countries Page 11
Slide 13: Use of Proceeds
Use of Proceeds Page 12
Slide 14: Use of Proceeds as at 8 August 2017
Use of Proceeds As at 8 August 2017 Amount allocated pursuant to reallocation of Use of proceeds Amount unutilised listing Amount allocated expenses utilised Balance S$’000 S$’000 S$’000 S$’000 Business expansion in Asia Pacific region (including Malaysia and 13,800 300 (12,565) (N1) 1,535 Singapore
Slide 15: 6 Months Financial Highlights
6 Months Financial Highlights for the period ended 30 June 2017 Page 14
Slide 16: Revenue
Revenue SGD’mil 6M2017 vs 6M2016 Group revenue was higher. The increase was attributable to revenue generated from JL Medical (Bukit Batok) Pte. Ltd., JL Medical (Sembawang) Pte. Ltd., JL Medical (Woodlands) Pte. Ltd. and JL Medical (Yew Tee) Pte. Ltd (collectively, the “JLM Companies”), which wer
Slide 17: Revenue – Malaysia
Revenue – Malaysia RM’mil SGD’mil 9.8% 3.9% Revenue from Malaysia operations in Ringgit Malaysia (“RM”) increased from RM37.8 million in 6M2016 to RM41.5 million in 6M2017, up 9.8% mainly due to increased number of patients visits. Singapore Dollar translated revenue from Malaysia operations in 6M
Slide 18: EBITDA and Profit After Tax
Earnings Before Interest Tax Depreciation and Amortisation (EBITDA) and Profit After Tax (PAT) SGD’000 EBITDA was S$5.4 million in 6M2017 as compared to S$4.9 million in 6M2016 mainly due to contribution from the JLM Companies in 6M2017 and increased patient visits from the Malaysia and Singapore
Slide 19: Cash Position
Cash Position Total cash and cash equivalents Unutilised IPO proceeds Cash balances SGD’mil Total cash and cash equivalents as at 30 June 2017 was S$22.1 million. No debts. Cash balances (exclude unutilised IPO proceeds) increased from S$18.9 million as at 31 December 2016 to S$20.6 million as a
Slide 20: Statement of Financial Position
Statement of Financial Position S$’000 30 June 31 December 2017 2016 Key Assets Plant and equipment 3,858 3,967 Intangible assets 38,742^ 39,111^ Trade and other receivables 2,430 2,171 Cash and cash equivalents 22,117 20,376 Key Liabilities Trade and other payables 3,102 4,919 Equity Total equity 6
Slide 21: Thank You
Thank You Page 20